Table 10.
Effect of different treatments on RANKL pathway markers of DEXA-induced osteoclast formation.
| Groups | RANKL | OPG | RANKL/OPG | |
|---|---|---|---|---|
| Control osteoblast cells (OB) | 1 ± 0.0000 a | 1 ± 0.0000 d | 1 ± 0.0000 a | |
| OB | CA 13 | 1.03 ± 0.02 a | 0.99 ± 0.03 d | 1.13 ± 0.01 b |
| OB | CA13/HA50 | 0.98 ± 0.01 a | 0.98 ± 0.02 d | 1.42 ± 0.04 d |
| OB | CA13/HA/BER100 | 1.08 ± 0.03 a | 1.32 ± 0.01 e | 1.22 ± 0.03 c |
| OB | CA13/HA/ME100 | 1.04 ± 0.02 a | 1.23 ± 0.12 e | 1.15 ± 0.01 b |
| Induction osteoclast cells (OC) | 13.7 ± 0.92 f | 0.41 ± 0.01 a | 23.5 ± 1.32 g | |
| OC | CA 13 | 11.1 ± 1.12 e | 0.45 ± 0.03 a | 21.2 ± 1.17 g |
| OC | CA13/HA50 | 8.32 ± 0.47 d | 0.74 ± 0.04 b | 14.3 ± 1.02 f |
| OC | CA13/HA/BER100 | 3.56 ± 0.08 b | 0.97 ± 0.03 d | 9.38 ± 0.08 e |
| OC | CA13/HA/ME100 | 4.57 ± 0.09 c | 0.83 ± 0.02 c | 10.2 ± 0.03 e |
Results are the means ± SD in each group. In each column, means with different letters are significantly different with each other where (a) the lowest mean, means with the same letters are significantly similar at p < 0.05.